Adagene Inc. — Regulatory Filings 2021

Apr 13, 2021

6-K 1 a21-12838_16k.htm 6-K

*UNITED STATES SECURITIES AND EXCHANGE COMMISSION*

*WASHINGTON, D.C. 20549*

*FORM 6-K*

*REPORT OF FOREIGN PRIVATE ISSUER*

*PURSUANT TO RULE 13a-16 OR 15d-16*

*UNDER THE SECURITIES EXCHANGE ACT OF 1934*

*For the Month of April 2021*

*Commission File Number: 001-39997*

*Adagene Inc.*

(Exact Name of Registrant as Specified in Its Charter)

*4F, Building C14, No. 218*

*Xinghu Street, Suzhou Industrial Park*

*Suzhou, Jiangsu Province, 215123*

*People’s Republic of China*

*+86-512-8777-3632*

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S -T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S -T Rule 101(b)(7): o

SEQ.=1,FOLIO='',FILE='C:\JMS\120681\21-12838-1\task10363447\12838-1-ba.htm',USER='120681',CD='Apr 13 13:27 2021'

*SIGNATURES*

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

By:
Name: Peter (Peizhi) Luo
Title: Chief Executive Officer
Date: April 13, 2021

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\120681\21-12838-1\task10363447\12838-1-ba.htm',USER='120681',CD='Apr 13 13:27 2021'

*EXHIBIT INDEX*

Exhibit	Description
99.1	Press Release titled “Adagene Presents Preclinical Data from Lead SAFEbody TM Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021”

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\120681\21-12838-1\task10363447\12838-1-ba.htm',USER='120681',CD='Apr 13 13:27 2021'